Kornimate/medical-research-clean huggingface dataset:
stroke prevention in sickle cell anemia (stop 2)

Conditions: Blood Disease; Cerebrovascular Accident; Anemia, Sickle Cell

Summary: to determine how long blood transfusions are needed for primary stroke prevention. also, to determine the duration of risk associated with abnormal transcranial doppler ultrasound (tcd) and to determine the specificity of the stroke risk model developed in stop 1 in patients with abnormal tcd measurements.

background: without intervention, 11 percent of children with sickle cell anemia will sustain a stroke before the age of 20. the stop 2 follows on the recently completed nhlbi trial, stroke prevention trial in sickle cell anemia (stop 1), which found that patients at high risk for stroke could be identified using transcranial doppler (tcd) ultrasound, and that the incidence of stroke could be reduced by 90 percent in those children by periodic blood transfusion for at least 36 months. however, chronic intermittent blood transfusions are cumbersome, expensive and associated with morbidity from iron overload. thus, this study to determine if transfusion can be safely halted after 30 months of treatment is critically important to the continued clinical care of patients with sickle cell disease at risk for stroke. design narrative: in this multicenter, randomized clinical trial, 100 children will be randomized to continue to receive periodic transfusion therapy and 50 to discontinue receiving periodic transfusion therapy. the primary endpoint will be the reversion of the transcranial doppler velocity levels to greater than 200 cm/second, indicating return of increased risk for overt stroke. recruitment will be in two phases. phase i will include those patients who began transfusions before april 1, 1999. these will come mainly from the stop 1 cohort. those who begin transfusions after april 1, 1999 but before april 1, 2001 will be eligible for phase ii of recruitment. all patients will receive quarterly tcd examinations. patients who revert to high risk will be offered return to transfusion. the overall design includes a three month start-up, the two phases of recruitment (established stop patients and new patients) for a total of 36 months, 18 months of observations after recruitment ends and then 3 months of wrap-up. the study completion date listed in this record was obtained from the "end date" entered in the protocol registration and results system (prs) record.

Eligibility criteria:
no eligibility criteria
paperless parotograph in evaluation of labour

Conditions: Labor Complication

Summary: using paperless partograph management of labour as simple tool to prevent obstructed labour or prolonged labour or its complications at the mother or her fetus

who partograph is very work load need more time and more stuff in both treaning and learning for plotting and for drowning but inside labour room needing simple partograph playing the simple partograph beast role in management of labour and stand test against time for saving live of labour women and her child paperless parotograph can help obestitricianes to talk decision about when to transferr the labourus women to higher centers on to make medical intervention or what time to end labour by caesarian section

Eligibility criteria:
inclusion criteria: * women ln active phase of labour * with single pregnanncy * living fetus * cephalic presentation * occipt anterior * 36 weak gestional age up to full term exclusion criteria: * preterm . .or women with antipartum hemorrhage . * or multipregnanncy * previous utrine surgery * or abnormal cardiotocograph(ctg )pattern * or any heart disease of mother or his fetus

Keywords: who partograpg.obstructed labour. managment of labour
emergency/compassionate use - muscular vsd occluder

Conditions: Muscular; Ventricular; Septal; Defects; VSD

Summary: expanded access to the amplatzer muscular vsd occluder


Eligibility criteria:
inclusion criteria: * emergency/compassionate use for patients not meeting the inclusion criteria for the amplatzer muscular vsd clinical trial
peg-ifn plus ribavirin combination therapy for older patients

Conditions: Hepatitis C Virus

Summary: the purpose of this study is to analyze the efficacy and safety of a combination therapy of pegylated interferon (peg-ifn) alpha-2b plus ribavirin (rbv) for older japanese patients (≧65years old) infected with hepatitis c virus (hcv) compared with younger patients(\< 65 years old).


Eligibility criteria:
inclusion criteria: * a prospective study of 2270 japanese patients aged 18 years or older treated with peg-ifn alpha-2b plus rbv was done between december 2004 and july 2008. * all positive for both antibody to hcv and hcv-rna for over six months and were enrolled. exclusion criteria: * clinical or biochemical evidence of hepatic decompensation. * advanced cirrhosis identified by large esophageal varices (f2 or f3). * history of gastrointestinal bleeding, ascites, encephalopathy, or hepatocellular carcinoma. * hemoglobin level \< 11.5g/l, white blood cell count \< 3×10９/ｌ，and platelet count \< 50×10９/ｌ. * concomitant liver disease other than hepatitis c(hepatitis b surface antigen positive or hiv positive). * excessive active alcohol consumption \> 60 g/day or drug abuse. * severe psychiatric disease. * antiviral or corticosteroid therapy within 12 months prior to the enrollment.

Keywords: hepatitis c virus pegylated interferon ribavirin older
hfcwo in hospitalized asthmatic children

Conditions: Bronchial Asthma; Asthma; Status Asthmaticus

Summary: to determine whether or not high frequency chest wall oscillation (in the form of the vesttm) is superior to regular asthma therapy in the management of children hospitalized with moderate to severe asthma.

a historically controlled pilot study was conducted in pediatric patients 18 months to 18 years of age hospitalized with a diagnosis of asthma or reactive airway disease and admitted to the pediatric intensive care unit. upon receiving informed consent, patients were treated with hfcwo therapy via the vest. the primary endpoint was time to readiness for discharge, lack of need for continued supportive care (e.g., intravenous fluid or oxygen), and bronchodilator treatments spaced at least four hours apart.

Eligibility criteria:
inclusion criteria: * any pediatric patient between the ages of 18 months and 18 years admitted to winthrop university hospital's pediatric floor or intensive care unit with a diagnosis of asthma or reactive airway disease exclusion criteria: * patients with chronic, comorbid respiratory conditions (e.g., cerebral palsy, cystic fibrosis) * those who regularly use hfcwo * any patient exhibiting an absolute contraindication to hfcwo therapy * absolute contraindications to using hfcwo include head and neck injury prior to stabilization, and active hemorrhage with hemodynamic instability

Keywords: asthma bronchial disease status asthmaticus high frequency chest wall oscillation the vest hfcwo
fast assessment of stenosis severity- fastii study

Conditions: Coronary Artery Disease

Summary: the multicenter fast (fast assessment of stenosis severity) study is a prospective observational multicenter study designed to evaluate the diagnostic accuracy of offline 3d-qca based ffr, using caas workstation (pie medical imaging, maastricht, the netherlands) in identifying hemodynamically significant coronary artery disease with pressure wire-based ffr (≤0.80) as the reference standard.

the multicenter fast study is a prospective observational multicenter international study in which offline computation of vffr is compared to conventional invasive, wire based ffr measurements. pressure wire based ffr will be performed in patients with at least one intermediate coronary lesion at the discretion of the operator (typically defined as a coronary artery lesion with a diameter stenosis of 30-70% by visual assessment). a total of 3 two-dimensional angiography images, will be recorded and exported to the caas workstation 8.0 (pie medical imaging, maastricht, the netherlands): two orthogonal views to create a 3d reconstruction of the coronary arteries and one view to ascertain the position of the ffr pressure wire. vffr will be calculated automatically, by using the invasively measured aortic root pressure. vffr measurements will be performed online by the different centers. in addition, all angiographic imaging data will be sent to an independent core laboratory (cardialysis, rotterdam, the netherlands) for offline analysis.

Eligibility criteria:
inclusion criteria: * patients ≥ 18 years * indication procedure: stable, unstable angina or non-st elevation acute coronary syndrome * diagnostic coronary angiography or pci with an indication to perform re-pci ffr assessment of at least one coronary artery lesion. exclusion criteria: * st-elevation myocardial infarction (stemi) * cardiogenic shock * severe hemodynamic instability * adenosine intolerance * lesions containing thrombus, left main lesions, grafts, arteries with collaterals

Keywords: fractional flow reserve coronary physiology 3d-qca percutaneous coronary intervention
a study to assess safety and efficacy of risankizumab using a new formulation in participants with moderate to severe plaque psoriasis

Conditions: Psoriasis

Summary: the primary objective of this study was to evaluate the safety and efficacy of risankizumab (150 mg/ml) administered by prefilled syringe (pfs) for the treatment of adult participants with moderate to severe plaque psoriasis.

this was a phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the safety and efficacy of risankizumab 150 mg/ml formulation in pfs in adult participants with moderate to severe plaque psoriasis. the study included a 30-day screening period, a 28-week treatment period with study visits at weeks 0, 4, 16 and 28, and a subsequent follow-up telephone call at approximately 20 weeks after the last dose of study drug. study drug dosing consisted of 3 self-administered, subcutaneous (sc) doses on weeks 0, 4, and 16. dosing on week 4 was self-administered at home.

Eligibility criteria:
inclusion criteria: * participant has diagnosis of chronic plaque psoriasis for at least 6 months before the baseline visit. * participant meets following disease activity criteria: * stable moderate to severe chronic plaque psoriasis, defined as greater than or equal to 10% body surface area (bsa) psoriasis involvement, static physician global assessment (spga) score of greater than or equal to 3, and psoriasis area severity index (pasi) greater than or equal to 12 at screening and baseline visit. * candidate for systemic therapy as assessed by the investigator. exclusion criteria: * participant has history of active skin disease other than psoriasis that could interfere with the assessment of psoriasis. * participant has history of erythrodermic psoriasis, generalized or localized pustular psoriasis, medication-induced or medication-exacerbated psoriasis, or new onset guttate psoriasis. * participant has previous exposure to risankizumab.

Keywords: risankizumab psoriasis plaque psoriasis
early oral hydration after thoracoscopic surgery

Conditions: Anesthesia; Intubation Complication

Summary: the goal of this clinical trial is to learn about the safety and feasibility of early oral hydration in patients receiving video-assisted thoracoscopic surgery after general anesthesia. the main questions aims to answer: * the safety and feasibility of oral hydration supplementation in the recovery room following general anesthesia. * the degree of improvement in sore throat and dry mouth after oral hydration. * the side effects and risks of oral hydration supplementation, such as the incidence of postoperative nausea and vomiting. * the impact of oral hydration supplementation in the recovery room following general anesthesia on hemodynamics. * patient satisfaction with oral hydration supplementation in the recovery room following general anesthesia. participants will receive a series of oral hydration from swab moistening, and ice cube hydration to water hydration in the recovery room. researchers will compare with the standard, no-hydration group to see if it is safe and feasible to hydrate patients in the recovery room.

anesthesiologists assess the removal of the endotracheal tube post-surgery and the patient is then transferred to the recovery room for rest. the principal investigator will evaluate the consciousness status and risk of nausea and vomiting to confirm eligibility for the trial. subsequently, the following grouping will be conducted: 1. experimental group * first, moisten the patient's throat with a cotton swab dipped in water. if no nausea or vomiting occurs after five minutes, proceed to the next stage. * provide an ice cube for the patient to hold in their mouth. if no nausea or vomiting occurs after ten minutes, proceed to the next stage. * offer 10-20ml water for the patient to drink under medical supervision. if no nausea or vomiting occurs and the patient requests more water, administer 10-20ml of water every ten minutes, assessing for any adverse effects each time. the total water intake should not exceed 500ml. 2. comparison group - standard care without any intervention evaluate the level of throat pain using vas (visual analogue scale) score, the incidence, timing, frequency of post-operative nausea and vomiting, the level of mouth dryness, the satisfaction of patients in recovery room, and the vital signs.

Eligibility criteria:
inclusion criteria: * males and females aged 18 to 70. * anesthesia physical status classification iii or below * body mass index 30 or below * elective video-assisted thoracoscopic surgery exclusion criteria: * pre-operative throat pain * impaired mental status * tendency to choke (inc. dysphagia, stroke hx.) * nil per os (npo) less than 8 hours * pregnancy * nausea and vomiting in operating room or post-anesthesia care unit

Keywords: early oral hydration sore throat
clinical trial to evaluate the food effect on the pharmacokinetics of eperisone hcl sr tablet 75mg

Conditions: Low Back Pain

Summary: the purpose of this study is to evaluate the food effect on the pharmacokinetics of eperisone hcl sr tablet

eperisone hydrochloride(muscle relaxant)

Eligibility criteria:
inclusion criteria: * healthy male subjects age between 20 and 55 signed informed consent exclusion criteria: * hypotension or hypertension has a history of allergy reaction of this drug or other drugs

Keywords: low back pain
effectiveness repetitive transcranial magnetic stimulation (rtms) in patients with chronic tinnitus

Conditions: Tinnitus

Summary: transcranial magnetic stimulation is used to modulate the auditory neural pathways caused by hearing loss and leading to the phantom auditory perception of sound in the absence of an external or internal acoustic stimulus.

tinnitus is the phantom auditory perception of sound in the absence of an external or internal acoustic stimulus. it is a frequent problem which can interfere significantly with the ability to lead a normal life. treatment is difficult. most available therapies focus on habituation rather than treating the cause. tinnitus is thought to be generated in the brain, as a result of functional reorganization of auditory neural pathways and tonotopic maps in the central auditory system, following damage to the peripheral auditory system. low-frequency rtms has been investigated for the treatment of hyperexcitability disorders such as auditory hallucinations and tinnitus. pilot data indicate that the beneficial effect of low-frequency rtms can be enhanced by high frequency rtms of the left dorsolateral prefrontal cortex (dlpfc). in the proposed study we investigate whether high frequency rtms of the dlpfc improves therapeutic efficacy of low-frequency rtms on tinnitus in a controlled trial.

Eligibility criteria:
inclusion criteria: * diagnosis of subjective chronic tinnitus * duration of tinnitus more than 3 months exclusion criteria: * objective tinnitus * treatable cause of the tinnitus * involvement in other treatments for tinnitus at the same time * clinically relevant psychiatric comorbidity * clinically relevant unstable internal or neurological comorbidity * history of or evidence of significant brain malformation or neoplasm, head injury * cerebral vascular events * neurodegenerative disorder affecting the brain or prior brain surgery; * metal objects in and around body that can not be removed * pregnancy * alcohol or drug abuse * prior treatment with tms

Keywords: tinnitus chronic subjective tinnitus transcranial magnetic stimulation sensation disorders hearing disorders
eribulin [halaven] use for the treatment of advanced breast cancer

Conditions: Metastatic Breast Cancer

Summary: the purpose of this study was to evaluate the efficacy and safety of eribulin in standard clinical practice in patients with locally recurrent or metastatic advanced breast cancer.

this was an observational, cross-sectional, retrospective, multicenter study conducted in spain. during the year after authorization of the drug by the european medicines agency (ema), patients in the compassionate use program (public sites) and patients treated in private sites (no purchase restrictions) who received at least 1 dose of treatment with eribulin per approved label at any of the 17 spanish sites with the highest numbers of treated cases during that period (minimum 3 patients/site) were enrolled in this observational study. approximately 112 patients will be enrolled in the study.

Eligibility criteria:
inclusion criteria: 1. patients diagnosed with locally recurrent or metastatic advanced breast cancer, previously treated with taxanes and anthracyclines, unless these were not indicated. 2. clinical and/or radiological documentation of location and extension of the disease at the time of starting treatment with eribulin. patients with measurable diseases and those patients who only have non-measurable lesions are eligible. 3. medical history documentation including analytical control data (blood count and serum chemistry including hepatic and renal functions) carried out at least one week before starting treatment with eribulin. (determining the ca15-3 tumor marker is not indispensable). 4. eribulin monotherapy (at least 1 dose) between april 2011 and march 2012, both inclusive. 5. availability of a medical history allowing monitoring of clinical progression of the patients during and after treatment with eribulin. exclusion criteria: 1. diagnosis of any type of cancer in the last 5 years, except for non-melanoma skin cancer, cervical intraepithelial neoplasia or contralateral breast cancer. 2. patients having received any other anti-tumor treatment, whether conventional or experimental, during the week prior to starting treatment with eribulin. treatment with bisphosphonate and corticoids is allowed if they are clinically indicated and started 28 days before treatment with eribulin. 3. lack of clinical status documentation after completing treatment with eribulin or, at least, after having been administered 3 initial cycles. this can arise in any of the following cases (they are not excluding): 1. patients whose medical history does not state the reason and date for interruption of treatment with eribulin and their subsequent clinical progression. 2. patients still undergoing treatment with eribulin on march 31, 2012, for whom there is no data for at least the first 3 cycles.

Keywords: eribulin mesylate halaven breast cancer
online resources to manage obesity and health risks in an employee wellness program

Conditions: Obesity

Summary: the purpose of this study is to determine whether different types of online health tools can aid overweight individuals in reducing their weight and managing their cardiovascular risk factors in the context of an employee wellness program.


Eligibility criteria:
inclusion criteria: * vanderbilt university employee * completion of the 2009 go for the gold health risk assessment (hra) * obesity defined by bmi \> 30 * identification of an additional risk factor on the hra by either (a) a personal history of diabetes, high blood pressure, or high cholesterol or (b) a reported cholesterol \>= 240 mg/dl, blood glucose \>= 126 mg/dl, a systolic blood pressure \>= 140 mm hg, or a diastolic blood pressure \>= 90 mm hg * permission to be contacted regarding health on the hra exclusion criteria: * pregnant females and those who become pregnant prior to completion of the study * age younger than 18 years or older than 65 years * non english speaking individuals

Keywords: obesity
efficacy and safety of the neodymium laser in treatment of urogenital tract diseases in women

Conditions: Genitourinary Syndrome of Menopause; Pelvic Floor Dysfunction; Vulvar Lichen Sclerosus

Summary: study objective: to evaluate the efficacy and safety of the magic max neodymium laser in the medical treatment of women with symptoms of genitourinary syndrome of menopausal, vulvar lichen sclerosus and pelvic floor muscle reduction.

study objective: to evaluate the efficacy and safety of the magic max neodymium laser in the medical treatment of women with symptoms of genitourinary syndrome of menopausal, vulvar lichen sclerosus and pelvic floor muscle reduction. materials and methods: 60 patients with diseases of the urogenital tract were enrolled into the study; they were treated with a neodymium (nd) laser: three 20-minute sessions every 28 ± 2 days. efficacy was assessed by means of the female sexual function index (fsfi), iciq-sf, pisq-12, sf36 survey forms, and a questionnaire to identify urinary disorders at the following time points: before treatment, one month after each session and 6 months after the last procedure.

Eligibility criteria:
inclusion criteria: * diseases of the urogenital tract * symptoms of genitourinary menopausal syndrome, * vulvar lichen sclerosus * pelvic floor muscle reduction exclusion criteria: * pregnancy * oncological diseases

Keywords: neodymium laser, gums, lichen sclerosus